The Starpax treatment is a revolutionary technology unlike any other on the planet. Itallows the drug to be transported directly to the tumor without passing through the bloodstream, leaving untargeted organs intact. Starpax Medical inc. has developed a unique system for the targeted non-systemic delivery of anticancer drugs to solid tumors. The system presents the ability to access hypoxic tumor areas usually not accessible by anti-cancer drugs administered intravenously, while limiting systemic exposure to these highly toxic agents. The proposed project includes 2 objectives aimed at (i) finalize the imaging methodology necessary for the clinical study protocol and (ii) carry out a validation study aimed at verifying the safety, tolerability and efficacy of the drug administration and intratumoral targeting via Magnetotaxi in adult patients with 4 types of solid tumors (rectal cancer, carcinoma of the head and neck, skin metastases f and pancreatic ductal adenocarcinoma). Starpax Medical has acquired a revolutionary technology for the treatment of cancer which is the result of 18 years of research in several university laboratories and hospitals in Quebec, which required more than 180 professionals in bioengineering and medicine. Starpax’s technology has the potential to treat 90% of cancers (solid tumors) without the harmful side effects of chemotherapy and radiation therapy. Starpax Medical is a Quebec company that has set itself the ultimate mission of making its technology accessible as quickly as possible to 84 million cancer patients. The development of new treatment options could generate significant benefits for patients and significant long-term savings in the healthcare system.